- Home
- TPVG vs CLLS Comparison
TPVG vs CLLS Comparison
Compare TPVG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- CLLS
- Stock Information
- Founded
- TPVG 2013
- CLLS 1999
- Country
- TPVG United States
- CLLS France
- Employees
- TPVG N/A
- CLLS N/A
- Industry
- TPVG Other Consumer Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- CLLS Health Care
- Exchange
- TPVG Nasdaq
- CLLS Nasdaq
- Market Cap
- TPVG 273.2M
- CLLS 299.0M
- IPO Year
- TPVG N/A
- CLLS 2007
- Fundamental
- Price
- TPVG $5.59
- CLLS $3.98
- Analyst Decision
- TPVG Hold
- CLLS Buy
- Analyst Count
- TPVG 6
- CLLS 1
- Target Price
- TPVG $6.38
- CLLS $8.00
- AVG Volume (30 Days)
- TPVG 344.0K
- CLLS 224.4K
- Earning Date
- TPVG 11-05-2025
- CLLS 11-03-2025
- Dividend Yield
- TPVG 16.49%
- CLLS N/A
- EPS Growth
- TPVG N/A
- CLLS N/A
- EPS
- TPVG 1.03
- CLLS N/A
- Revenue
- TPVG $97,395,000.00
- CLLS $63,438,000.00
- Revenue This Year
- TPVG N/A
- CLLS N/A
- Revenue Next Year
- TPVG $6.79
- CLLS $66.76
- P/E Ratio
- TPVG $5.42
- CLLS N/A
- Revenue Growth
- TPVG N/A
- CLLS 223.09
- 52 Week Low
- TPVG $5.24
- CLLS $1.10
- 52 Week High
- TPVG $8.50
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- TPVG 42.33
- CLLS 56.39
- Support Level
- TPVG $5.24
- CLLS $3.93
- Resistance Level
- TPVG $5.63
- CLLS $5.48
- Average True Range (ATR)
- TPVG 0.17
- CLLS 0.39
- MACD
- TPVG 0.02
- CLLS 0.03
- Stochastic Oscillator
- TPVG 53.61
- CLLS 46.22
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.